Paul R. Fonteyne
Independent DirectorMr. Paul R. Fonteyne, MS, MBS, MBA, serves as the Chairman of DalCor Pharmaceuticals Canada Inc and Dalcor Pharmaceuticals US LLC. He served as a Member of Board of Managers of Corium, LLC (also known as Corium, Inc.) from November 2023 to 2026 and was its Independent Chairman of Board of Managers since 2024 until 2026. He serves as Independent Director at Apnimed, Inc. since October 2023. He is Co-Founder, Advisor & Director of Allyx Therapeutics, Inc. He serves as Independent Director at Apnimed, Inc. since joining in October 2, 2023. He has experience in corporate leadership in biopharmaceuticals. He serves as Executive in Residence at Canaan Management, Inc. He served as a Director at Covetrus, Inc. since May 2021 until 2022. He served as an Independent Director of Apellis Pharmaceuticals, Inc. since April 2020 until May 14, 2026. He has been an Independent Director of Amylyx Pharmaceuticals, Inc. since March 2021. He is the Chief Executive Officer of Thyron Pharmaceuticals Inc, a company he founded in April 2021. He serves as the President and Director at Thyron Pharmaceuticals, Inc. He served as an Independent Director of AMAG Pharmaceuticals, Inc. since October 8, 2019 until November 16, 2020. He served as a Director of resTORbio, Inc. since December 11, 2017 until 2020. He has experience in the biopharmaceutical industry, including many years of leadership roles in the United States and globally with Boehringer-Ingelheim. He also held commercial leadership roles at Merck and Co. Inc. for many years and at Abbott Laboratories for many years. He has been an Independent Director of Ypsomed Holding AG since July 2018 and serves as an Independent Vice President of the Board since 2020. He served as a Director of National Pharmaceutical Council and served as its Chair. He served as the United States Country Managing Director, President from November of 2011 and Chief Executive Officer of Boehringer Ingelheim USA Corporation since 2012 until March 01, 2018 and subsequently Chairman until his retirement in January 2019. He has served on the board of PhRMA and chaired the National Pharmaceutical Council. He serves as Chief Executive Officer and President of Boehringer Ingelheim Pharmaceuticals, Inc. Previously, he served as Senior Corporate Vice President in Boehringer Ingelheim GmbH from 2009 to 2011. From 2003 to 2008, he served as an Executive Vice President, Head of Marketing and Sales for Prescription Medicines at Boehringer-Ingelheim Pharmaceuticals, Inc. He has been the Chief Executive Officer, President and Managing Director- Boehringer Ingelheim USA Corp of C. H. Boehringer Sohn AG & Co. KG. Prior to 2003, he served in numerous leadership positions at Merck and Co. Inc, including Vice President of Sales in North Central US, Vice President of Marketing and Senior Director of Marketing from 1995 until 2004. He held various positions at Abbott Laboratories from 1987 until 1995. He serves on the advisory board of the Brigham and Women’s Hospital Lung Center and the board of PhRMA. He had been an Independent Director of Gelesis Holdings, Inc. since January 2022 until October 30, 2023 and previously served as a member of the Gelesis, Inc. board of directors from May 2018 to January 2022. He serves as Chairman of DalCor. He has experience in the biopharmaceutical industry. He served as Chair of an American cancer Society initiative for New England (CEOs against Cancer). He received his MBA from Carnegie-Mellon University and his MS in Chemical Engineering from the Polytechnic School at the University of Brussels.
Positions
- Company NameAmylyx Pharmaceuticals, Inc.Stock CodeAMLXPositionIndependent DirectorColleagues
- JBJoshua B. CohenCo-Founder, Co-CEO & Director
- GMGeorge Mclean MilneIndependent Chairman of the Board
- JBJustin B. KleeCo-CEO & Director
- JMJames M. FratesChief Financial Officer
- CLCamille L. BedrosianChief Medical Officer
- THTom HolmesChief Technical Operations Officer
- RERudolph Emile TanziChairman of The Scientific Advisory Board
- PRPaul R. FonteyneIndependent Director
- Company NameApnimed, Inc.Stock CodeAPMDPositionIndependent DirectorColleagues
- KRKevin Robert LindCEO & Director
- PJPaul J. SekhriIndependent Chair of the Board
- LGLawrence G. MillerFounder & Vice Chair of the Board
- DPDennis Patrick MolnarPresident & COO
- LTLuigi Taranto MontemurroCo-Founder & Chief Scientific Officer
- MBMichael B. KellyChief Financial Officer
- GLGary L. SenderIndependent Director
